Please login to the form below

Not currently logged in
Email:
Password:

EMA’s Paediatric Committee elects new leaders

Dirk Mentzer and Henk van den Berg elected as chair and vice-chair

Dirk Mentzer The European Medicines Agency's (EMA) Paediatric Committee (PDCO) last week elected Dirk Mentzer and Henk van den Berg chair and vice-chair, respectively, at its September meeting. Both have been elected for a three-year term. 

A paediatrician by training, Dr Mentzer is currently head of the pharmacovigilance unit at the Paul-Ehrlich Institut in Frankfurt, Germany.  He is an expert in paediatric specialist training, including neonatology and paediatric accident and emergency admissions. 

Dr Van den Berg is a consultant in paediatric haematology / oncology at the Medicines Evaluation Board in Utrecht, the Netherlands.  His areas of expertise include paediatric haematology, clinical pharmacology and medical education. 

On their election, Mentzer and van den Berg thanked outgoing chair Daniel Brasseur, who has left the PDCO to become a member of the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP).

Both Mentzer and van den Berg have been members of the PDCO since it was established in 2007. The committee's main role is to assess the content of paediatric investigation plans (PIPS). It meets for three days each month at the EMA in London.

19th September 2013

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics